KR20050059001A - 치료적 처리를 위한 조성물 및 방법 - Google Patents
치료적 처리를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20050059001A KR20050059001A KR1020047021602A KR20047021602A KR20050059001A KR 20050059001 A KR20050059001 A KR 20050059001A KR 1020047021602 A KR1020047021602 A KR 1020047021602A KR 20047021602 A KR20047021602 A KR 20047021602A KR 20050059001 A KR20050059001 A KR 20050059001A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- agent
- antibody
- patient
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18902502A | 2002-07-01 | 2002-07-01 | |
US10/189,025 | 2002-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20050059001A true KR20050059001A (ko) | 2005-06-17 |
Family
ID=29999592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047021602A KR20050059001A (ko) | 2002-07-01 | 2003-06-30 | 치료적 처리를 위한 조성물 및 방법 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1551452A4 (ru) |
JP (1) | JP2005534679A (ru) |
KR (1) | KR20050059001A (ru) |
CN (1) | CN1678348A (ru) |
AU (1) | AU2003279657A1 (ru) |
BR (1) | BR0312484A (ru) |
CA (1) | CA2491427A1 (ru) |
IL (1) | IL166062A0 (ru) |
MX (1) | MXPA05000271A (ru) |
PL (1) | PL374431A1 (ru) |
RU (1) | RU2005101622A (ru) |
WO (1) | WO2004002528A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003144A2 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
CA2561835A1 (en) * | 2004-03-30 | 2005-10-13 | Den Kgl. Veterinaer-Og Landbohojskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors |
ES2641570T3 (es) | 2004-03-31 | 2017-11-10 | University Of Utah Research Foundation | Sistemas de suministro macromoleculares para imagenología no invasiva, evaluación y tratamiento de artritis y otras enfermedades inflamatorias |
ES2527961T3 (es) | 2005-09-26 | 2015-02-02 | Medarex, L.L.C. | Anticuerpos monoclonales humanos para CD70 |
US8580267B2 (en) | 2008-12-19 | 2013-11-12 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
ES2877171T3 (es) * | 2014-07-08 | 2021-11-16 | Sanford Burnham Med Res Inst | Moduladores de PSGL-1 y usos de los mismos |
RU2766000C2 (ru) * | 2016-01-08 | 2022-02-07 | АльтруБио Инк. | Четырехвалентные антитела к psgl-1 и их применения |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05244987A (ja) * | 1992-02-28 | 1993-09-24 | Unitika Ltd | 抗硫酸化チロシン抗体,その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ |
US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
IL140700A0 (en) * | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
AU774419C (en) * | 1998-10-30 | 2005-03-03 | Genetics Institute, Llc | Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists |
AU2000248423A1 (en) * | 2000-05-11 | 2001-11-20 | National Tsing Hua University | Compositions and methods for induction of active autoimmunity |
CA2409652A1 (en) * | 2000-05-15 | 2001-11-22 | Giorgio Massimini | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
CZ20031982A3 (cs) * | 2000-12-29 | 2004-09-15 | Bio-Technology General Corp. | Izolované molekuly zahrnující epitopy obsahující sulfatované sloučeniny, protilátky proti takovým epitopům a jejich použití |
PL365758A1 (en) * | 2000-12-29 | 2005-01-10 | Savient Pharmaceuticals,Inc. | Specific human antibodies for selective cancer therapy |
-
2003
- 2003-06-30 CN CNA03820441XA patent/CN1678348A/zh active Pending
- 2003-06-30 CA CA002491427A patent/CA2491427A1/en not_active Abandoned
- 2003-06-30 KR KR1020047021602A patent/KR20050059001A/ko not_active Application Discontinuation
- 2003-06-30 AU AU2003279657A patent/AU2003279657A1/en not_active Abandoned
- 2003-06-30 MX MXPA05000271A patent/MXPA05000271A/es unknown
- 2003-06-30 BR BRPI0312484-3A patent/BR0312484A/pt not_active IP Right Cessation
- 2003-06-30 RU RU2005101622/15A patent/RU2005101622A/ru not_active Application Discontinuation
- 2003-06-30 JP JP2004518133A patent/JP2005534679A/ja active Pending
- 2003-06-30 WO PCT/US2003/020604 patent/WO2004002528A1/en active Application Filing
- 2003-06-30 EP EP03742338A patent/EP1551452A4/en not_active Withdrawn
- 2003-06-30 PL PL03374431A patent/PL374431A1/xx not_active Application Discontinuation
-
2004
- 2004-12-30 IL IL16606204A patent/IL166062A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1551452A4 (en) | 2006-08-30 |
MXPA05000271A (es) | 2005-03-31 |
CA2491427A1 (en) | 2004-01-08 |
IL166062A0 (en) | 2006-01-15 |
RU2005101622A (ru) | 2006-01-27 |
WO2004002528A9 (en) | 2004-11-18 |
WO2004002528A1 (en) | 2004-01-08 |
PL374431A1 (en) | 2005-10-17 |
EP1551452A1 (en) | 2005-07-13 |
AU2003279657A1 (en) | 2004-01-19 |
JP2005534679A (ja) | 2005-11-17 |
BR0312484A (pt) | 2008-01-08 |
CN1678348A (zh) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090220486A1 (en) | Antibodies and uses thereof | |
US20040002450A1 (en) | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20040001822A1 (en) | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20040001839A1 (en) | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
US20040202665A1 (en) | Compositions and methods for therapeutic treatment | |
KR20030091953A (ko) | 황산화된 부분을 함유하는 에피토프를 포함하는 분리된분자, 그러한 에피토프에 대한 항체, 및 그들의 용도 | |
US7132510B2 (en) | Specific human antibodies for selective cancer therapy | |
JP2005503756A5 (ru) | ||
KR20030091952A (ko) | 선택적인 암 치료용의 특이적 인간 항체 | |
KR20060011925A (ko) | 항체 및 이의 용도 | |
US20050152906A1 (en) | Specific human antibodies | |
KR20050059001A (ko) | 치료적 처리를 위한 조성물 및 방법 | |
US20080274100A1 (en) | Antibodies and uses thereof | |
JP2007528711A (ja) | 抗体及びその使用 | |
EP1646401A2 (en) | Specific human antibodies | |
US20040208877A1 (en) | Antibodies and uses thereof | |
AU2002246738A1 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |